Thompson Investment Management Inc. Has $74,000 Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Thompson Investment Management Inc. trimmed its position in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 95.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,479 shares of the company's stock after selling 231,668 shares during the quarter. Thompson Investment Management Inc.'s holdings in Bausch Health Companies were worth $74,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Mountain Hill Investment Partners Corp. bought a new stake in shares of Bausch Health Companies in the 4th quarter valued at about $56,000. Bank of Nova Scotia acquired a new position in Bausch Health Companies in the 4th quarter valued at about $83,000. One68 Global Capital LLC acquired a new position in Bausch Health Companies in the 4th quarter valued at about $90,000. Balyasny Asset Management L.P. acquired a new position in Bausch Health Companies in the 4th quarter valued at about $97,000. Finally, Alpine Global Management LLC acquired a new position in Bausch Health Companies in the 4th quarter valued at about $114,000. 78.65% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Royal Bank of Canada increased their target price on shares of Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. Wall Street Zen lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. One investment analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $7.42.

Bausch Health Companies Stock Up 9.2%

Shares of NYSE BHC traded up $0.51 during midday trading on Friday, reaching $6.02. 11,490,808 shares of the company were exchanged, compared to its average volume of 2,611,854. The stock's 50-day moving average price is $4.85 and its 200-day moving average price is $6.42. The stock has a market cap of $2.23 billion, a P/E ratio of -50.12, a PEG ratio of 0.37 and a beta of 0.28. Bausch Health Companies Inc. has a one year low of $3.96 and a one year high of $9.85.

Insider Transactions at Bausch Health Companies

In other news, Director John Paulson bought 754,134 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were acquired at an average price of $5.05 per share, for a total transaction of $3,808,376.70. Following the completion of the acquisition, the director now directly owns 27,193,169 shares in the company, valued at approximately $137,325,503.45. This represents a 2.85% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last 90 days, insiders have acquired 2,788,608 shares of company stock worth $14,700,257. Company insiders own 8.05% of the company's stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.